Evaluation of a human immunodeficiency virus test algorithm utilizing a recombinant protein enzyme immunoassay

Area of Science:

• Immunology
• Virology
• Medical Diagnostics

Background:

• Western blots are standard for human immunodeficiency virus (HIV) confirmation but are time-consuming and expensive.
• Many HIV antibody-negative samples undergo unnecessary Western blot testing, increasing costs and workload.

Purpose of the Study:

• To evaluate a recombinant protein-based enzyme immunosorbent assay (EIA) as an adjunct to viral lysate EIA for HIV testing.
• To determine if the CBC Recombigen HIV EIA can reduce the number of Western blot tests performed on antibody-negative samples.

Main Methods:

• 2,212 serum samples were screened using viral lysate EIA.
• Samples were then tested in parallel using the Cambridge BioScience (CBC) Recombigen HIV EIA and Western blot.
• Sensitivity, specificity, and predictive values of the CBC EIA were calculated.

Main Results:

• The CBC Recombigen HIV EIA demonstrated high sensitivity (99.9%) and specificity (99.7%).
• Positive and negative predictive values were also high, at 99.7% and 99.9%, respectively.
• The assay proved effective in identifying truly antibody-negative samples.

Conclusions:

• The CBC Recombigen HIV EIA is a highly sensitive and specific diagnostic tool for HIV testing.
• Its high negative predictive value makes it valuable for reducing unnecessary Western blot confirmations.
• Implementing this EIA can optimize HIV testing algorithms, saving time and resources.